Qiagen (NYSE:QGEN) Receives $51.50 Consensus Target Price from Brokerages

Shares of Qiagen (NYSE:QGEN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are presently covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $51.50.

QGEN has been the topic of several analyst reports. HSBC downgraded Qiagen from a "buy" rating to a "hold" rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Jefferies Financial Group restated a "buy" rating and set a $54.00 price objective (up from $42.00) on shares of Qiagen in a research note on Tuesday, December 10th. Morgan Stanley reiterated an "equal weight" rating and issued a $48.00 target price (down previously from $50.00) on shares of Qiagen in a research note on Monday. Finally, Hsbc Global Res raised shares of Qiagen to a "hold" rating in a research report on Thursday, October 17th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in shares of Qiagen by 806.5% in the 3rd quarter. GAMMA Investing LLC now owns 562 shares of the company's stock worth $26,000 after purchasing an additional 500 shares in the last quarter. Toronto Dominion Bank bought a new position in shares of Qiagen in the second quarter worth about $27,000. Massmutual Trust Co. FSB ADV lifted its position in shares of Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company's stock valued at $39,000 after buying an additional 243 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Qiagen during the 3rd quarter valued at approximately $53,000. Finally, Headlands Technologies LLC increased its holdings in Qiagen by 396.6% in the 2nd quarter. Headlands Technologies LLC now owns 2,741 shares of the company's stock worth $113,000 after acquiring an additional 2,189 shares in the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

Qiagen Stock Up 0.6 %

Shares of NYSE QGEN traded up $0.29 on Thursday, reaching $45.23. 630,516 shares of the company's stock traded hands, compared to its average volume of 616,523. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The business's 50 day simple moving average is $43.94 and its two-hundred day simple moving average is $43.87. Qiagen has a 12 month low of $39.03 and a 12 month high of $47.44. The company has a market cap of $10.32 billion, a price-to-earnings ratio of 115.97, a price-to-earnings-growth ratio of 3.52 and a beta of 0.37.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.